Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2005

View Archived Issues

GSK-3 inhibition highlighted as important new avenue for mood disorder therapies / News in Context

Electrophysiological characterization of two 5-HT1A receptor inverse agonists

TB-1-099: A novel allosteric modulator of SERT

Chymase inhibition represents a novel strategy for treatment of scleroderma

Experimental evidence for 5-HT7's role in emotion

Genentech licenses TAP technology for use with therapeutic antibodies

DOR and Dowpharma sign joint development agreement for BT-VACC

Phase I study of Progenics' novel HIV entry inhibitor completes enrollment

GCAN-101 begins phase II study for metastatic cancers

NDA accepted for filing for InKine's next-generation purgative product

Milestone in Arena and Merck & Co. cardiovascular collaboration

Valeant to develop Viramidine in Japan

Teva to acquire Ivax

HCV-I.E.T. studied in phase I/II trial for hepatitis C

HIV-1 protease inhibitor lopinavir demonstrates antimalarial activity in vitro

Tirapazamine attenuates tumor metastasis in vivo

Nippon Boehringer Ingelheim to solely market Alesion

New therapeutics for cancer disclosed in recent patents

Novel TACE inhibitors claimed in recent patent literature

Paratek studies new broad-spectrum antibiotic PTK-0796 in phase I trial

Noxafil recommended for approval in Europe

Expanded indication for Remicade recommended for approval in Europe

Kepivance receives positive opinion in Europe for oral mucositis

Positive opinion handed down for Xolair in Europe

Recent patents describe novel antiinfective agents

New release of Prous Science Integrity(R) with technology and content enhancements